These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 32203789)
1. Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification. Wang Y; He X; Li C; Ma Y; Xue W; Hu B; Wang J; Zhang T; Zhang F Eur J Med Chem; 2020 May; 193():112235. PubMed ID: 32203789 [TBL] [Abstract][Full Text] [Related]
2. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin. Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010 [TBL] [Abstract][Full Text] [Related]
3. Development of novel N-aryl-2,4-bithiazole-2-amine-based CYP1B1 degraders for reversing drug resistance. Yao X; Mao J; Zhang H; Xiao Y; Wang Y; Liu H Eur J Med Chem; 2024 Jun; 272():116488. PubMed ID: 38733885 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors. Dong J; Wang Z; Cui J; Meng Q; Li S Eur J Med Chem; 2020 Feb; 187():111938. PubMed ID: 31830634 [TBL] [Abstract][Full Text] [Related]
5. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship. Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Binding Affinity Evaluation of Cytochrome P450 1B1 Targeted Chelators. Chen D; Fan Q; Xu T; Dong J; Cui J; Wang Z; Wang J; Meng Q; Li S Anticancer Agents Med Chem; 2022; 22(2):261-269. PubMed ID: 33820523 [TBL] [Abstract][Full Text] [Related]
7. Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme. Sharma R; Gatchie L; Williams IS; Jain SK; Vishwakarma RA; Chaudhuri B; Bharate SB Bioorg Med Chem Lett; 2017 Dec; 27(24):5400-5403. PubMed ID: 29150398 [TBL] [Abstract][Full Text] [Related]
8. Identification of CYP1B1-specific candidate inhibitors using combination of in silico screening, integrated knowledge-based filtering, and molecular dynamics simulations. Kumar R; Gupta D Chem Biol Drug Des; 2016 Nov; 88(5):730-739. PubMed ID: 27300691 [TBL] [Abstract][Full Text] [Related]
9. Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives. Poirier D; Roy J; Cortés-Benítez F; Dutour R Bioorg Med Chem Lett; 2016 Nov; 26(21):5272-5276. PubMed ID: 27687674 [TBL] [Abstract][Full Text] [Related]
10. Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by α-naphthoflavone analogs. Wang Y; Hu B; Zhang Y; Wang D; Luo Z; Wang J; Zhang F Phys Chem Chem Phys; 2021 Sep; 23(36):20230-20246. PubMed ID: 34474468 [TBL] [Abstract][Full Text] [Related]
11. Inhibitors of cytochrome P450 (CYP) 1B1. Dutour R; Poirier D Eur J Med Chem; 2017 Jul; 135():296-306. PubMed ID: 28458135 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance. Williams IS; Joshi P; Gatchie L; Sharma M; Satti NK; Vishwakarma RA; Chaudhuri B; Bharate SB Bioorg Med Chem Lett; 2017 Aug; 27(16):3683-3687. PubMed ID: 28711350 [TBL] [Abstract][Full Text] [Related]
13. Identification of 19-( Shoieb SM; El-Sherbeni AA; El-Kadi AOS Drug Metab Dispos; 2019 Feb; 47(2):67-70. PubMed ID: 30420405 [TBL] [Abstract][Full Text] [Related]
15. The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells. Ruparelia KC; Lodhi S; Ankrett DN; Wilsher NE; Arroo RRJ; Potter GA; Beresford KJM Bioorg Med Chem Lett; 2019 Jun; 29(11):1403-1406. PubMed ID: 30935796 [TBL] [Abstract][Full Text] [Related]
16. Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors. Liu Q; Miao Y; Wang X; Lv G; Peng Y; Li K; Li M; Qiu L; Lin J Eur J Med Chem; 2020 Jan; 186():111905. PubMed ID: 31785819 [TBL] [Abstract][Full Text] [Related]
17. Drug repurposing for the identification of new Bcl-2 inhibitors: In vitro, STD-NMR, molecular docking, and dynamic simulation studies. Rahman N; Zafar H; Atia-Tul-Wahab ; Sheikh S; Jabeen A; Choudhary MI Life Sci; 2023 Dec; 334():122181. PubMed ID: 37858717 [TBL] [Abstract][Full Text] [Related]
18. Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors. Dong J; Huang G; Cui Q; Meng Q; Li S; Cui J Eur J Med Chem; 2021 Jan; 209():112895. PubMed ID: 33069055 [TBL] [Abstract][Full Text] [Related]
19. Structure-Based Drug Design and Synthesis of Novel Mao J; Wang D; Xu P; Wang Y; Zhang H; Wang S; Xu F; Wang J; Zhang F J Med Chem; 2022 Dec; 65(24):16451-16480. PubMed ID: 36512763 [TBL] [Abstract][Full Text] [Related]
20. Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity. Dutour R; Roy J; Cortés-Benítez F; Maltais R; Poirier D J Med Chem; 2018 Oct; 61(20):9229-9245. PubMed ID: 30216063 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]